HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Siva, R. Articles by Pavord, I. D. Search for Related Content PubMed PubMed Citation Articles by Siva, R. Articles by Pavord, I. D.

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial

Institute for Lung Health, Dept of Respiratory Medicine and Thoracic Surgery, Glenfield Hospital, Leicester, UK.

CORRESPONDENCE: I. D. Pavord, Institute for Lung Health, Glenfield Hospital, Groby Road, Leicester, LE3 9PQ, UK. Fax: 44 1162367768. E-mail: ian.pavord{at}uhl-tr.nhs.uk

Keywords: Airway inflammation, chronic obstructive pulmonary disease, corticosteroids, eosinophils, exacerbations

Received: November 8, 2006
Accepted January 21, 2007

Evidence suggests that eosinophilic airway inflammation is important in the pathogenesis of severe chronic obstructive pulmonary disease (COPD) exacerbations. The present authors tested the hypothesis that a management strategy that aims to reduce sputum eosinophil counts is associated with a reduction in exacerbations of COPD.

A total of 82 patients with COPD were randomised into two groups. One group was treated according to traditional guidelines (British Thoracic Society (BTS) group) and the other (sputum group) was treated with the additional aim of minimising eosinophilic airway inflammation, assessed using the induced sputum eosinophil count. The primary outcome was exacerbations, which were categorised as mild, moderate or severe.

The frequency of severe exacerbations per patient per year was 0.5 and 0.2 in the BTS and sputum groups, respectively (mean reduction 62%). The majority of this benefit was confined to patients with eosinophilic airway inflammation. There was no difference in the frequency of mild and moderate exacerbations. The average daily dose of inhaled or oral corticosteroids during the trial did not differ between the groups. Out of 42 patients in the sputum group, 17 required regular oral corticosteroids to minimise eosinophilic airway inflammation.

A management strategy that aims to minimise eosinophilic airway inflammation, as well as symptoms, is associated with a reduction in severe exacerbations of chronic obstructive pulmonary disease.

This article has been cited by other articles:

				D. C. Todd, R. A. McIvor, S. O. Pugsley, and G. Cox Approach to chronic obstructive pulmonary disease in primary care Can Fam Physician, May 1, 2008; 54(5): 706 - 711. [Abstract] [Full Text] [PDF]

				W. MacNee Update in Chronic Obstructive Pulmonary Disease 2007 Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 820 - 829. [Full Text] [PDF]